Patients with cancer expect to derive a meaningful clinical benefit from anticancer treatments, especially considering that such therapies are associated with adverse events and, often,

substantial financial costs. We have evaluated new anticancer agents approved by the FDA in 2015 and 2016 using the ESMO Magnitude of Clinical Benefit Scale and ASCO Value Framework, and

conclude that many agents only offer marginal value. Access through your institution Buy or subscribe This is a preview of subscription content, access via your institution ACCESS OPTIONS

Access through your institution Access Nature and 54 other Nature Portfolio journals Get Nature+, our best-value online-access subscription $32.99 / 30 days cancel any time Learn more

Contact customer support REFERENCES * Saltz, L. B. Progress in cancer care: the hope, the hype, and the gap between reality and perception. _J. Clin. Oncol._ 26, 5020–5021 (2008). Article 

Google Scholar  * Booth, C. M. & Eisenhauer, E. A. Progression-free survival: meaningful or simply measurable? _J. Clin. Oncol._ 30, 1030–1033 (2012). Article  Google Scholar  * Booth,

C. M. & Tannock, I. Reflections on medical oncology: 25 years of clinical trials — where have we come and where are we going? _J. Clin. Oncol._ 26, 6–8 (2008). Article  Google Scholar  *

Booth, C. M. _ et al_. Evolution of the randomized controlled trial in oncology over three decades. _J. Clin. Oncol._ 26, 5458–5464 (2008). Article  Google Scholar  * Seruga, B. _ et al_.

Absolute benefits of medical therapies in phase III clinical trials for breast and colorectal cancer. _Ann. Oncol._ 21, 1411–1418 (2010). Article  CAS  Google Scholar  * Cherny, N. I. _ et

al_. A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology

Magnitude of Clinical Benefit Scale (ESMO-MCBS). _Ann. Oncol._ 26, 1547–1573 (2015). Article  CAS  Google Scholar  * Schnipper, L. E. _ et al_. Updating the American Society of Clinical

Oncology value framework: revisions and reflections in response to comments received. _J. Clin. Oncol._ 34, 2925–2934 (2016). Article  Google Scholar  * Del Paggio, J. C. _ et al_. Do

contemporary randomized controlled trials meet ESMO thresholds for meaningful clinical benefit? _Ann. Oncol._ http://dx.doi.org/10.1093/annonc/mdw538 (2016). * Tap, W. D. _ et al_.

Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial. _Lancet_ 388, 488–497 (2016). Article  CAS 

Google Scholar  * Schlumberger, M. _ et al_. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. _N. Engl. J. Med._ 372, 621–630 (2015). Article  Google Scholar  * Truven

Health Analytics. RED BOOK: a comprehensive, consistent drug pricing resource. _Micromedex_ http://micromedex.com/products/product-suites/clinical-knowledge/redbook (2017). Download

references ACKNOWLEDGEMENTS C.M.B. is supported as the Canada Research Chair in Population Cancer Care. AUTHOR INFORMATION AUTHORS AND AFFILIATIONS * Departments of Oncology and Public

Health Sciences, Queen's University, University Avenue, Kingston, K7L 3N6, Ontario, Canada Christopher M. Booth * Department of Medicine, Division of Medical Oncology, University of

Toronto, King's College Circus, Toronto, M5S, Ontario, Canada Joseph C. Del Paggio Authors * Christopher M. Booth View author publications You can also search for this author inPubMed 

Google Scholar * Joseph C. Del Paggio View author publications You can also search for this author inPubMed Google Scholar CORRESPONDING AUTHOR Correspondence to Christopher M. Booth. ETHICS

DECLARATIONS COMPETING INTERESTS The authors declare no competing financial interests. SUPPLEMENTARY INFORMATION SUPPLEMENTARY INFORMATION S1 (TABLE) Clinical benefit of anticancer agents

approved by the FDA in 2015–2016 (PDF 228 kb) POWERPOINT SLIDES POWERPOINT SLIDE FOR TABLE 1 RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Booth, C.,

Del Paggio, J. Approvals in 2016: questioning the clinical benefit of anticancer therapies. _Nat Rev Clin Oncol_ 14, 135–136 (2017). https://doi.org/10.1038/nrclinonc.2017.18 Download

citation * Published: 20 February 2017 * Issue Date: March 2017 * DOI: https://doi.org/10.1038/nrclinonc.2017.18 SHARE THIS ARTICLE Anyone you share the following link with will be able to

read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing

initiative